Group One Trading
AVTX icon

Group One Trading’s Avalo Therapeutics AVTX Stock Holding History

Group One Trading’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Buy
16,600
+16,500
+16,500% +$258K ﹤0.01% 3942
2025
Q4 		$1.82K Buy
+100
New +$1.69K ﹤0.01% 7580
2022
Q4 		– Sell
-8
Closed -$6K – 7214
2022
Q3 		$6K Buy
8
+7
+700% +$7.59K ﹤0.01% 6730
2022
Q2 		$1K Sell
1
-2
-67% -$2.68K ﹤0.01% 7511
2022
Q1 		$6K Hold
3
– – ﹤0.01% 7356
2021
Q4 		$16K Sell
3
-1
-25% -$6K ﹤0.01% 7094
2021
Q3 		$28K Buy
4
+2
+100% +$16.2K ﹤0.01% 6952
2021
Q2 		$23K Buy
+2
New +$16.8K ﹤0.01% 7098
2021
Q1 		– Hold
0
– – – 7440
2018
Q4 		– Sell
-7
Closed -$90K – 4859
2018
Q3 		$90K Buy
+7
New +$91.8K ﹤0.01% 3604

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Group One Trading's AVTX Position: Q1 2026 in Review

Group One Trading sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 1 share — an estimated $16 sold.

Group One Trading first reported a position in AVTX in Q1 2021 and held it in 20 quarters. The position peaked at $50K in Q2 2021. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Group One Trading reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 1 Avalo Therapeutics share in Q1 2026, an estimated $16.
  • Group One Trading first reported a position in Avalo Therapeutics in Q1 2021 and held it in 20 quarters.
  • Group One Trading's Avalo Therapeutics position peaked at $50K in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.